In summary, these findings suggest that cholesterol metabolism plays a pivotal role in FAK-dependent sorafenib resistance in HCC cells, providing a mechanistic link between FAK signaling and therapeutic resistance. The gene discussed is PTK2; the disease is hepatocellular carcinoma.